Finding early signs of pancreatic cancer using blood tests.
Development of a panel of multiplex biomarkers for the early detection of pancreatic ductal adenocarcinoma and high-risk lesions
This study is looking for ways to use blood tests to find pancreatic cancer early in people who are at higher risk, so we can catch it sooner and help save lives.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10890753 on NIH RePORTER |
What this research studies
This research focuses on developing a panel of blood biomarkers to detect pancreatic ductal adenocarcinoma (PDAC) and its precursors at an early stage. The approach involves identifying high-risk individuals through clinical evaluations and then using serum biomarkers for regular testing to monitor their risk of developing PDAC. By implementing a two-step surveillance strategy, the research aims to improve early detection and potentially save lives by catching the disease before it progresses. Patients will be monitored over time to assess changes in their risk levels.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a family history of pancreatic cancer or those diagnosed with precursors like intraductal papillary mucinous neoplasms (IPMN).
Not a fit: Patients with no risk factors for pancreatic cancer or those already diagnosed with advanced pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier diagnosis of pancreatic cancer, significantly improving survival rates.
How similar studies have performed: Previous research has shown promise in using biomarkers for early cancer detection, indicating that this approach could be effective.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Chan, Daniel Wanyui — Johns Hopkins University
- Study coordinator: Chan, Daniel Wanyui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.